Drug Trial Radar · NCT04843709
A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Jul 26, 2021
Primary completion
Mar 20, 2024
Study completion Jul 26, 2024
Sponsor
- Lead sponsor
- Lepu Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of MRG004A in patients with Tissue Factor positive advanced or metastatic solid tumors.
Conditions
- Advanced or Metastatic Solid Tumors
Interventions
MRG004ADrug
Administrated intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD)Time frame: DLT will be evaluated during the first treatment cycle (Day 1-21)
- Recommended Phase II Dose (RP2D)Time frame: Baseline to study completion (up to 24 months)
- Objective Response Rate (ORR)Time frame: Baseline to study completion (up to 24 months)
- Adverse Events (AEs)Time frame: From signing informed consent until 45 days after the last dose of MRG004A
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
Chao Family Comprehensive Cancer Center
Orange, California
Memorial Sloan Kettering 60th Street Outpatient Center
New York, New York
Gabrail Cancer Center Research
Canton, Ohio
The Christ Hospital Cancer Center
Cincinnati, Ohio
Gettysburg Cancer Center
Gettysburg, Pennsylvania
Virginia Cancer Specialists
Fairfax, Virginia
Hunan Cancer Hospital
Changsha, Hunan, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.